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Background: Most Crohn’s disease (CD) genes discovered in recent years are associated with biological systems
critical to the development of this disease. TGFB1 and IL10 are cytokines with important roles in CD. The aim of this
study was to evaluate the association between CD, its clinical features and TGFB1 and IL10 gene polymorphisms.
Methods: This case–control study enrolled 91 patients and 91 controls from the state of Bahia, Brazil. Five single
nucleotide polymorphisms (SNPs) were studied in the TGFB1 gene (codon 10 T > C - rs1800470; codon 25 G > C -
rs1800471) and IL10 gene (−1082 A > G - rs1800896; -819 T > C - rs1800871; -592 A > C - rs1800872). An analysis of
the genetic polymorphisms was performed using a commercial kit. A comparison of allele frequencies and
genotypes was estimated by calculating the odds ratio (OR) with a confidence interval adjusted via the Bonferroni
test for a local alpha of 1%. A stratified analysis was applied for gender, race and smoking history. Patients with CD
were characterized according to the Montreal classification.
Results: The C allele and CC genotype of the TGFB1 gene rs1800470 were both significantly associated with CD.
The stratified analysis showed no confounding factors for the co-variables of gender, race and smoking history. The
IL10 gene rs1800896 G allele was significantly associated with age at diagnosis of CD, while the T allele of the IL10
gene rs1800871 was significantly associated with perianal disease. The SNPs rs1800871 and rs1800872 were in 100%
linkage disequilibrium.
Conclusions: TGFB1 gene polymorphisms may be associated with susceptibility to the development of CD, and
IL10 gene polymorphisms appear to influence the CD phenotype in this admixed population.
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Crohn’s disease (CD) pathogenesis is multifactorial, and
there appears to be a significant interaction between its
genetic, environmental and immunological factors [1,2].
The critical importance of immune regulation in inflam-
matory bowel disease (IBD) has been recognized, and
impairment in immune tolerance to the intestinal micro-
biota appears to be the primary defect associated with
this disease [3,4]. It is interesting to note that TGFB1 and
IL10 are the two major immune regulatory cytokines* Correspondence: neoalmeida@yahoo.com.br
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reproduction in any medium, provided the or[5-10]. Most CD genes discovered in recent years are asso-
ciated with biological systems critical to the development
of CD, such as innate and adaptive immunity, stress re-
sponse, autophagy and mucosal barrier [11,12].
TGFB1 is fundamental in maintaining the intestinal
epithelial cell homeostasis through its action on modu-
lating T cell activity, dendritic cell function and apop-
tosis [5-7,10]. The central role of IL10 in the balance of
intestinal mucosa immunology is its ability to inhibit the
production of proinflammatory cytokines and to regulate
the differentiation and proliferation of T and B lympho-
cytes and NK and antigen presenting cells [5,8-10]. Both
TGFB1 and IL10 cytokines play important roles in CD.
Animal studies demonstrated the importance of thesel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The neutralization of TGFB1 increases Th1 and Th17 re-
sponses, and IL10 constrains Th17 cells in patients with
CD [6,14]. A defect in TGFB1 production has been ob-
served in patients with CD, and the deregulation of IL10
has been associated with early-onset and severe CD [15,16].
TGFB1 is also involved in fibrosis and stricture formation
in CD [17].
Differences in cytokine production have been linked to
polymorphisms in gene promoter regions [18-22]. Indi-
vidual differences in cytokine synthesis could explain the
susceptibility to CD and its phenotypic heterogeneity. Stud-
ies about the influence of TGFB1 and IL10 genetic poly-
morphisms on the pathogenesis of inflammatory bowel
disease (IBD) have been published with controversial re-
sults, and most subjects were Caucasians [19,20,23-30].
The TGFB1 gene has at least two polymorphisms lo-
cated in the exon 1 region at rs1800470 and rs1800471,
which are the most frequently studied polymorphisms
in our local population [31,32]. A previous Australian
study showed an association between polymorphisms
at rs1800471 and CD [33]. The most commonly evalu-
ated polymorphisms in the IL10 gene are identified in
the promoter regions from rs18004896, rs1800871 and
rs1800872 [19,20,23,25-32]. These genes are closely re-
lated to the expression of IL10 [18,20].
The aim of this study was to analyze the association
between CD and the TGFB1 (codon 10 T > C - rs1800470;
codon 25 G > C - rs1800471) and IL10 (−1082 A >G - rs1
800896; -819 T > C - rs1800871; -592 A > C - rs1800872)
gene polymorphisms and to examine the association be-
tween these polymorphisms and the clinical features of
CD, such as age at diagnosis, location, and behavior of the
disease in a mixed-race population.
Methods
This was a case–control study. We evaluated patients
from outpatient gastroenterology clinics at the University
Hospital Prof. Edgard Santos and at the General Hospital
Roberto Santos in Salvador, Bahia. The patients and con-
trols were enrolled between March 2006 and May 2007.
We included patients 18 years or older who had a
diagnosis of Crohn’s disease, as established by the clinical,
radiological, endoscopic and histopathological features de-
scribed in the criteria of Lennard-Jones [34]. We excluded
first-degree relatives of patients who had been included
in the study and patients with indeterminate colitis. The
classification for CD was based on the Montreal criteria,
which include age at diagnosis, behavior, and location [35].
The ethnic profile was performed using the Krieger criteria
[36]. Patients were considered smokers if they had smoked
seven or more cigarettes per week for at least one year.
The control group comprised individuals from either
outpatient clinics who were 18 years old or older, hadbeen evaluated at the same period of time and had a
diagnosis of gastroesophageal reflux disease (GERD) (81
patients) or functional dyspepsia (10 patients). These sub-
jects were required not to have had any neoplastic, in-
fectious or inflammatory diseases, peptic ulcers, diarrhea,
hematochezia, fistulas, family history of IBD, or abdominal
pain without a specific diagnosis.
To obtain genomic DNA, 10 mL of whole blood was
collected from each patient and stored at - 4°C in EDTA
tubes until DNA extraction. Genomic DNA was purified
using the commercial EZ-DNA kit (Biological Industries,
Kibbuts Beit Haemek, Israel) according to the manufac-
turer’s instructions. The five single nucleotide polymor-
phisms (SNPs) studied were rs1800470 (codon 10 T > C)
and rs1800471 (codon 25 G > C) in the TGFB1 gene and
rs1800896 (−1082 A > G), rs1800871 (−819 T > C), and
rs1800872 (−592 A >C) in the IL10 gene. The SNPs were
genotyped with the Cytokine Genotyping Tray Kit (One
Lambda, Canoga Park, CA) according to the manufacturer’s
instructions. The results were interpreted using maps of the
genotyping plates supplied by the manufacturer.
Adherence to the Hardy-Weinberg equilibrium for each
polymorphism was tested for both case and control groups
using the program GENEPOP [37]. A comparison of allele
frequencies and genotypes in the different groups was esti-
mated by calculating the odds ratio (OR) with an adjusted
confidence interval (CI) of 99.8% and global α = 0.2% for
a local alpha of 1% (Bonferroni adjustment). The co-
variables of interest were gender, racial group (evaluated as
Whites or African-descendants), and smoking. To analyze
the effects of confounding factors and modifiers on the
main association, we performed a stratified analysis using
estimated ORs with 99% confidence intervals, Mantel-
Haenszel adjusted ORs and the Mantel-Haenszel chi-
square test. Because no significance was found for a local
alpha of 1%, the Bonferroni correction was not considered.
Logistic regression was not performed due to insufficient
data. To evaluate the association between the polymor-
phisms and phenotype characteristics of CD, the OR was
calculated and Fisher’s exact test was performed, yielding
p-values that were adjusted using the Bonferroni method.
The global alpha was 0.167%, and the CI was adjusted to
99.83% considering a local alpha of 1%.
Informed written consent was obtained from all sub-
jects, and the study protocol was approved by the Ethics
Committee of the Institution (Maternidade Climério de
Oliveira - Federal University of Bahia).
Results
We evaluated 182 subjects, of whom 91 had a definite
diagnosis of CD and 91 were controls. The mean age
of the patients with CD was 38.0 ± 12.8 years (range 18–
75 years, median 37 years), while the control patients had a
mean age of 50.3 ± 13.6 years (range 21–88 years, median
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CD. The distribution of racial groups was similar between
the cases and controls. There was a higher frequency of
smoking history (current or previous) among the controls.
The demographic and clinical characteristics of CD pa-
tients and controls are shown in Table 1. When gender,
race, and smoking history were compared, there were no
statistically significant differences between the cases and
controls (data not shown).
All polymorphisms adhered to the Hardy-Weinberg
equilibrium in both the case and control groups. The
allele frequencies and genotype distribution for TGFB1
polymorphisms (rs1800470, rs1800471) in the CD patients
and controls are shown in Table 2. The C allele of rs1
800470 was more frequent in the case group and was
associated with CD (p = 0.001, OR = 2.19, 99.8% CI = 1.1-
4.42). The CC genotype of rs1800470 was more frequentTable 1 Demographic and clinical characteristics of the
CD patients and controls
91 Cases (n%) 91 Controls (n%)
• Age
Mean ± SD 38 ±12.8 50,3 ± 13.6
• Gender
Female 54 (59.3) 67 (73.6)
Male 37 (40.7) 24 (26.4)
• Race group
African-descendent 80 (87.9) 82 (90.1)
White 11 (12.1) 09 (09.9)
• Smoking
No 71 (78.0) 64 (70.3)
Yes 20 (22.0) 27 (29.7)
• Age at diagnosis , n = 91
A1≤ 16 years 12 (13.2)
A2 17–40 years 55 (60.4)
A3 > 40 years 24 (26.4)
• Location , n = 82
L1 ± L4 Ileum 17 (20.7)
L2 ± L4 Colon 21 (25.6)




• Behavior, n = 90
B1 ± P Non-stricturing,
non-penetrating
62 (68.9)
B2 ± P Stricturing 13 (14.4)
B3 ± P Penetrating 15 (16.7)
P Perianal disease modifier 40 (44.4)
n (%) Number of individuals (percent).in the patients with CD compared with the controls (p =
0.001, OR = 4.05, 99.8% CI = 1.31-13.2). These results were
statistically significant after a Bonferroni correction. We
did not observe any association between TGFB1 geno-
types and the CD phenotype.
The allele frequencies and genotypes of the IL10 poly-
morphisms (rs1800896, rs1800871 and rs1800872) were
similar for both the cases and controls (Table 3). The
SNPs rs1800871 and rs1800872 were in 100% linkage
disequilibrium. The frequencies of the alleles for these
IL10 SNPs according to the phenotype characteristics of
CD are shown in Table 4. The G allele of rs1800896 was
more frequent in patients who were 16 years old or
younger at diagnosis (p = 0.001, OR = 4.32, 99.83% CI =
1.0022-18.62). An analysis of the association between
disease location and IL10 SNPs was not statistically sig-
nificant (data not shown). We also found a significantly
higher frequency of the T allele of rs1800871 in the IL10
gene in patients with perianal disease (p < 0.0001, OR =
7.7, 99.83% CI = 2.53-26.90). These results were statisti-
cally significant after a Bonferroni correction.
The stratified analysis by gender, racial group and smok-
ing history variables in our study showed that none of
these factors modified the effect or confounded the associ-
ation between the studied polymorphisms and CD.
Discussion
When conducting a case–control genetic association study,
the selection of controls is an important issue. This control
group should comprise subjects of the same population as
that of the cases enrolled [38]. The control group com-
prised patients treated at the same clinic with similar
epidemiological characteristics who were from the same
geographical area and had a diagnosis of a clinical condi-
tion not associated with the studied polymorphisms. In
addition, the controls were prospectively evaluated in the
same period of time in which the cases were enrolled.
GERD is a motor disorder not genetically determined, and
no studies have shown an association between the studied
polymorphisms and functional dyspepsia. Both the case
and control groups were similar in terms of gender and
race. Previous studies from Brazil have shown a genetic ad-
mixture from Portuguese, Amerindian and African genetic
backgrounds in the population of all studied geographic
areas, including the population of Bahia, regardless of the
skin color of the individuals [39,40].
Animal studies have shown that a reduction in TGFB1
affects oral tolerance and results in impaired mucosal
immunity [41]. Del Zotto et al. performed an interesting
study in Italy and observed that low levels of TGFB1 were
present in the intestinal lamina propria of CD patients
compared with controls [15]. Our polymorphism analysis
of the TGFB1 cytokine gene showed a positive association
between CD and the C allele of SNP rs1800470. However,
Table 2 Allele frequencies and genotype distribution for the TGFB1 polymorphisms in CD patients and controls
91 Cases n (%) 91 Controls n (%) OR [99.8% CI] PB P value
• rs1800470 (codon 10 T > C)
T allele 81 (45.5%) 116 (63.7%) 2.19 [1.10- 4.42] 0.005 0.001
C allele 101 (55.5%) 66 (36.3%)
• Genotype
TT 22 (24.1%) 39 (42.8%) Reference
TC 37 (40.7%) 38 (41.8%) 1.73 [0.66- 4.78] 0.820 0.164
CC 32 (35.2%) 14 (15.4%) 4.05 [1.31- 13.20] 0.005 0.001
• rs1800471 (codon 25 G > C)
G allele 166 (91.2%) 176 (96.7%) 2.83 [0.77-10.89] 0.150 0.030
C allele 16 (8.8%) 6 (3.3%)
• Genotype
GG 77 (84.6%) 85 (93.4%) Reference
GC 12 (13.2%) 6 (6.6%) 2.21 [0.53-11.08] 0.710 0.142
CC 2 (2.2%) 0 (0%) ¨¨¨¨¨ ¨¨¨¨¨¨ ........ ¨¨¨¨¨¨
n (%) Number of alleles or genotypes (percent).
PB Bonferroni adjustment.
¨¨¨¨¨¨ Insufficient number.
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show an association between TGFB1 polymorphisms and
CD [23,24,42]. Additionally, the TGFB1 gene has not been
associated with CD in genome-wide association studies
(GWAS) [11,12]. The confirmed CD susceptibility loci ex-
plained only 23.2% of the disease heritability [11]. These
findings could suggest the existence of other genetic varia-
tions not captured via GWAS. One possible explanation
for the differences between our results and those previ-
ously reported is that we investigated African-descent CDTable 3 Allele frequencies and genotype distribution for the
91 cases n (%) 91 controls n (%)
• rs1800896 (−1082 A > G)
Aallele 116 (63.7%) 123 (67.6%)
G allele 66 (36.3%) 59 (32.4%)
• Genotype
AA 41 (45.0%) 40 (44.0%)
GA 34 (37.4%) 43 (47.2%)
GG 16 (17.6%) 8 (8.8%)
• rs1800871 (−819 T > C)*
C allele 116 (63.7%) 106 (58.2%)
Tallele 66 (36.3%) 76 (41.8%)
• Genotype
CC 36 (39.6%) 28 (30.8%)
CT 44 (48.4%) 50 (54.9%)
TT 11 (12.0%) 13 (14.3%)
n(%) Number of alleles or genotypes (percent).
*SNPs rs1800871 and rs1800872 were in 100% linkage disequilibrium.patients while the other studies evaluated Caucasian pop-
ulations. Therefore, the TGFB1 gene could be directly as-
sociated with susceptibility to CD in this population or in
a linkage disequilibrium with other genetic markers. This
conclusion is biologically plausible, but additional studies
are needed to validate these data. The allele frequencies of
rs1800470 in TGFB1 in our CD patients were similar to
the frequency of a healthy control group reported by
Pereira et al., who evaluated genetic polymorphisms in
patients with hepatitis C in the State of Bahia [32]. ThisIL10 polymorphisms in CD patients and controls
OR [99% CI] P value
1.19 [0.66- 2.14] 0.44
Reference
0.77 [0.32- 1.84] 0.42





Table 4 Allele frequencies of the IL10 polymorphisms according to the Crohn’s disease phenotypes
rs1800896 rs1800871*
AlleleG Allele T
N n (%) OR PB P value n (%) OR PB P value
[99.83 CI] [99.83 CI]
• Age at diagnosis
A1 12 16 (66.7) 4.32 0.006 0.001 6 (25) 0.54 1.000 0.260
[1.0022 – 8.62] [0.07 - 2.59]
A2 + A3 79 50 (31.6) 60 (38)
• Behavior
B1 62 42 (33.9) 0.68 1.000 0.316 47 (37.9) 1.4 1.000 0.401
[0.23 - 2.05] [0.46 - 4.58]
B2 + B3 28 24 (42.9) 17 (30.4)
P 40 30 (37.5) 1.07 1.000 0.877 48 (60) 7.77 < 0.0001 < 0.0001
[0.38 - 2.96] [2.53 - 26.90]
A1 ≤ 16 years, A2 17–40 years, A3 > 40 years, B1 Non-stricturing, non-penetrating, B2 Stricturing, B3 Penetrating, P Perianal disease modifier.
N Number of patients, n (%) Number of alleles (percent), PB Bonferroni adjustment.
*SNPs rs1800871 and rs1800872 were in 100% linkage disequilibrium.
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obtained in the hepatitis C study. A patient’s family history
of IBD was considered an exclusion criterion in our con-
trol group.
TGFB1 is a potent fibrogenic agent that induces the
proliferation of fibroblasts and the synthesis of collagen
and extracellular matrix [43,44]. Changes in TGFB1 sig-
naling have also been identified in the mucosa overlying
strictures in CD [17]. Previous reports have suggested a
role for TGFB1 polymorphisms in stricturing CD and a
shorter time to intestinal resection [33]. However, in agree-
ment with our findings, Cantor et al. found no association
between the TGFB1 polymorphism and the phenotypic
characteristics of CD [23].
The development of spontaneous chronic enterocolitis
in genetically modified mice that do not produce the cyto-
kine IL10 has long been known [5,13,16]. Many studies
have shown no association between several IL10 polymor-
phisms and susceptibility to CD [23,25-27,45]. However,
studies from Spain, New Zealand, and Mexico showed
that these IL10 polymorphisms were associated with CD
susceptibility [19,28,46]. More recently, a meta-analysis
showed an association between the SNPs from rs1800896
and CD susceptibility [47]. We have not been able to repli-
cate these findings in our sample.
The IL10 gene has been identified as a novel CD locus
in GWAS studies [11,12]. Experimental studies have
shown that a low production of IL10 is associated with
more severe and complex CD [16]. Although usually
considered an inhibitory cytokine, IL10 also stimulates
B-cell proliferation [48]. Genetic studies evaluating CD pa-
tients demonstrated an association between IL10 polymor-
phisms and the severity of disease, including stricturingbehavior and pediatric onset [30,49]. We observed a posi-
tive association between the G allele of rs1800896 and age
at diagnosis of CD. Some studies indicated that the G allele
was associated with increased IL10 production [18,20]. The
SNPs at rs1800896 appear to dictate early-onset disease, in
which the development is likely influenced by genetic ra-
ther than environmental factors. The other studied IL10
SNP (rs1800871) was associated with perianal disease,
suggesting that it may be useful in predicting CD behavior.
It is possible that the association between specific IL10 pro-
moter polymorphisms and severe CD may be correlated
with the stimulatory effects of IL10, but additional func-
tional investigation is necessary to confirm this hypothesis.
CD is considered a frequent disease in Caucasian popula-
tions; however, most CD patients in our studied population
were not Caucasian. The study of CD in different popula-
tions may increase our understanding about the genetics
and environmental factors that might interfere with the
development CD.
Conclusion
In conclusion, this study has shown that TGFB1 polymor-
phisms may be associated with susceptibility to CD, while
IL10 polymorphisms may influence CD phenotypes. Thus,
the polymorphic sites of both genes appear to be particu-
larly important in our population. However, further multi-
center studies with larger samples are needed to evaluate
the reproducibility of our findings. CD is a disease that
greatly impacts patient quality of life, and despite its rising
frequency, the pathophysiologic mechanisms of CD are un-
clear and present a challenge. A better understanding of the
various genetic polymorphisms that affect different popula-
tions may eventually lead to the better management of CD.
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